These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives. John M; Gopinath D; Jagesh R Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465 [TBL] [Abstract][Full Text] [Related]
3. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878 [TBL] [Abstract][Full Text] [Related]
4. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association. Lee S Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644 [TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Vivian EM Drugs Context; 2014; 3():212264. PubMed ID: 25598831 [TBL] [Abstract][Full Text] [Related]
6. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Kim Y; Babu AR Diabetes Metab Syndr Obes; 2012; 5():313-27. PubMed ID: 22977310 [TBL] [Abstract][Full Text] [Related]
7. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care. Danne T; Biester T; Kordonouri O Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741 [TBL] [Abstract][Full Text] [Related]
8. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Brunton SA Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213 [TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes? Saisho Y Diseases; 2020 May; 8(2):. PubMed ID: 32403420 [TBL] [Abstract][Full Text] [Related]
10. SGLT2 inhibitors - an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin. Seufert J Diabetes Metab Syndr Obes; 2015; 8():543-54. PubMed ID: 26609242 [TBL] [Abstract][Full Text] [Related]
11. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science. Cruz JE; Ahuja T; Bridgeman MB Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393 [TBL] [Abstract][Full Text] [Related]
12. Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus. Lopez JM; Macomson B; Ektare V; Patel D; Botteman M Am Health Drug Benefits; 2015 Sep; 8(6):309-18. PubMed ID: 26557225 [TBL] [Abstract][Full Text] [Related]
13. Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus. Takebayashi K; Inukai T J Clin Med Res; 2017 Sep; 9(9):745-753. PubMed ID: 28811850 [TBL] [Abstract][Full Text] [Related]
14. The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes. Steen O; Goldenberg RM Can J Diabetes; 2017 Oct; 41(5):517-523. PubMed ID: 28942789 [TBL] [Abstract][Full Text] [Related]
16. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor. Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118 [TBL] [Abstract][Full Text] [Related]
18. Effects of SGLT2 Inhibitors on Atherosclerosis: Lessons from Cardiovascular Clinical Outcomes in Type 2 Diabetic Patients and Basic Researches. Xu J; Hirai T; Koya D; Kitada M J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011882 [TBL] [Abstract][Full Text] [Related]